Avelumab with axitinib for untreated advanced renal cell carcinoma

2.1 Avelumab (Bavencio, Merck-Pfizer) with axitinib (Inlyta, Pfizer) 'is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma'.

2.2 The dosage schedules are available in the avelumab summary of product characteristics and the axitinib summary of product characteristics.

2.3 Avelumab is available at a list price of £768.00 per 200-mg vial or £3,072.00 per 800-mg fixed dose (excluding VAT; companies' submission).

2.4 Axitinib is available in 4 strengths, which all come in packs of 56 tablets. The list prices are: £703.40 for 1-mg tablets, £2,110.20 for 3-mg tablets, £3,517.00 for 5-mg tablets and £4,923.80 for 7-mg tablets (excluding VAT; companies' submission).

2.5 There is a commercial arrangement for avelumab plus axitinib. This makes avelumab plus axitinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the companies' responsibility to let relevant NHS organisations know details of the discount.